Ready to upload
Adverse Occurrence type:
Time to detection:
Alerting signals, symptoms, evidence of occurrence:
Patient with blood group B was incorrectly transfused with a unit of A2 group red blood cells, and developed clinical and immunohematologic reactions; patient was treated with eculizumab, but hemoglobinemia and hemoglobinuria was present several hours after transfusion.
Demonstration of imputability or root cause:
Hemoglobinuria, hemoglobemia, transient increased bilirubin.
Suggest new keywords:
anti-A2, acute hemolytic transfusion reaction (AHTR),
Weinstock, C., Mohle, R., Dorn, C., Weisel, K., Hchsmann, B., Schrezenmeier, H. and Kanz, L. (2014). Successful use of eculizumab for treatment of an acute hemolytic reaction after ABO-incompatible red blood cell transfusion, Transfusion 55(3):605-610. DOI: 10.1111/trf.12882;